Healthcare Industry News: Ranbaxy Laboratories
News Release - October 29, 2007
Pfizer to Appeal German Court Decision in Lipitor Patent Case; Company Notes That Ruling Has No Immediate Commercial ImpactNEW YORK--(HSMN NewsFeed)--Pfizer Inc said today that the Federal Patent Court in Munich, Germany has revoked the company’s patent covering atorvastatin calcium, the active ingredient in Lipitor. The patent at issue in the lawsuit (EP 409,281) expires in July 2010.
Pfizer said it will appeal the decision, a process expected to take two to three years. The ruling will have no effect on a pending challenge to the basic atorvastatin patent in Germany by the same two companies. Pfizer also noted that the decision will have no impact on patent litigation involving Lipitor in other jurisdictions around the world.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.